Deadly encounter: Ubiquitin meets apoptosis

Nature Reviews Molecular Cell Biology

Volumn 3, Issue 2, 2002, Pages 112-121

  Jesenberger, Veronika ^a   Jentsch, Stefan ^a  

^a MAX PLANCK INSTITUTE OF BIOCHEMISTRY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEASOME; UBIQUITIN; CASPASE; CYSTEINE PROTEINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INHIBITOR OF APOPTOSIS PROTEIN; INSECT PROTEIN; MULTIENZYME COMPLEX; PROTEIN; PROTEIN BCL 2; PROTEIN P53;

ANTIGEN PRESENTATION; APOPTOSIS; CELL CYCLE; CELL DEATH; EUKARYOTE; LYSOSOME; PRIORITY JOURNAL; PROTEIN DEGRADATION; REGULATORY MECHANISM; REVIEW; TRANSCRIPTION REGULATION; ANIMAL; BIOLOGICAL MODEL; HUMAN; PHYSIOLOGY; SIGNAL TRANSDUCTION;

EUKARYOTA;

ANIMALS; APOPTOSIS; CASPASES; CYSTEINE ENDOPEPTIDASES; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; INSECT PROTEINS; MODELS, BIOLOGICAL; MULTIENZYME COMPLEXES; NF-KAPPA B; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITIN;

EID: 0036483901     PISSN: 14710072     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrm731     Document Type: Review

References (110)

1. Meier, P., Finch, A. & Evan, G. Apoptosis in development. Nature 407, 796-801 (2000).
2. Krammer, P. H. CD95s deadly mission in the immune system. Nature 407, 789-795 (2000).
3. Rich, T., Allen, R. L. & Wyllie, A. H. Defying death after DNA damage. Nature 407, 777-783 (2000).
4. Hengartner, M. O. The biochemistry of apoptosis. Nature 407, 770-776 (2000).
5. Hacker, G. The morphology of apoptosis. Cell Tissue Res. 301, 5-17 (2000).
6. Adams, J. M. & Cory, S. Life-or-death decisions by the Bcl-2 protein family. Trends Biochem. Sci. 26, 61-66 (2001).
7. Deveraux, Q. L. & Reed, J. C. IAP family proteins-suppressors of apoptosis. Genes Dev. 13, 239-252 (1999).
8. Jentsch, S. & Schlenker, S. Selective protein degradation: a journey's end within the proteasome. Cell 82, 881-884 (1995).
9. Pickart, C. M. Mechanisms underlying ubiquitination. Annu. Rev. Biochem. 70, 503-533 (2001).
10. Weissman, A. M. Themes and variations on ubiquitylation. Nature Rev. Mol. Cell Biol. 2, 169-178 (2001).
11. Schwartz, L. M., Myer, A., Kosz, L., Engelstein, M. & Maier, C. Activation of polyubiquitin gene expression during developmentally programmed cell death. Neuron 5, 411-419 (1990).
12. Odowski, R. Z. The role of the ubiquitin-proteasome pathway in apoptosis. Cell Death Differ. 6, 303-313 (1999).
13. Wojcik, C. Proteasomes in apoptosis: villains or guardians? Cell Mol. Life Sci. 56, 908-917 (1999).
14. Dawson, S. P. et al. Developmental changes of the 26S proteasome in abdominal intersegmental muscles of Manduca sexta during programmed cell death. J. Biol. Chem. 270, 1850-1858 (1995).
15. Jones, M. E., Haire, M. F., Kloetzel, P. M., Mykles, D. L. & Schwartz, L. M. Changes in the structure and function of the multicatalytic proteinase (proteasome) during programmed cell death in the intersegmental muscles of the hawkrnoth, Manduca sexta. Dev. Biol. 169, 436-447 (1995).
16. Duan, H. et al. SAG, a novel zinc RING finger protein that protects cells from apoptosis induced by redox agents. Mol. Cell Biol. 19, 3145-3155 (1999).
17. Lisztwan, J., Imbert, G., Wirbelauer, C., Gstaiger, M. & Krek, W. The von Hippel-Lindau tumor suppressor protein is a component of an E3 ubiquitin-protein ligase activity. Genes Dev. 13, 1822-1833 (1999).
18. Pause, A. et al. The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins. Proc. Natl Acad. Sci. USA 94, 2156-2161 (1997).
19. Gorospe, M. et al. Protective function of von Hippet-Lindau protein against impaired protein processing in renal carcinoma cells. Mol. Cell. Biol. 19, 1289-1300 (1999).
20. Schoenfeld, A. R. et al. The von Hippel-Lindau tumor suppressor gene protects cells from UV-mediated apoptosis. Oncogene 19, 5851-5857 (2000).
21. Devarajan, P. et al. The von Hippel-Lindau gene product inhibits renal cell apoptosis via Bcl-2-dependent pathways. J. Biol. Chem. 276, 40599-40605 (2001).
22. Raasi, S., Schmidtke, G. & Groettrup, M. The ubiquitin-like protein FAT10 forms covalent conjugates and induces apoptosis. J. Biol. Chem. 276, 35334-35343 (2001).
23. Takayama, S. et al. Cloning and functional analysis of BAG-1: a novel Bcl-2-binding protein with anti-cell death activity. Cell 80, 279-284 (1995).
24. Mikula, M. et al. Embryonic lethality and fetal liver apoptosis in mice lacking the c-raf-1 gene. EMBO J. 20, 1952-1962 (2001).
25. Jesenberger, V. et al. Protective role of Raf-1 in Salmonella-induced macrophage apoptosis. J. Exp. Med. 193, 353-364 (2001).
26. Wang, H. G., Takayama, S., Rapp, U. R. & Reed, J. C. Bcl-2 interacting protein, BAG-1, binds to and activates the kinase Raf-1. Proc. Natl Acad. Sci. USA 93, 7063-7068 (1996).
27. Matsuzawa, S., Takayama, S., Froesch, B. A., Zapata, J. M. & Reed, J. C. p53-inducible human homologue of Drosophila seven in absentia (Siah) inhibits cell growth: suppression by BAG-1. EMBO J. 17, 2736-2747 (1998).
28. Thress, K., Henzel, W., Shillinglaw, W. & Kornbluth, S. Scythe: a novel reaper-binding apoptotic regulator. EMBO J. 17, 6135-6143 (1998).
29. Thress, K., Evans, E. K. & Kornbluth, S. Reaper-induced dissociation of a Scythe-sequestered cytochrome c-releasing activity. EMBO J. 18, 5486-5493 (1999).
30. Shinohara, K. et al. Apoptosis induction resulting from proteasome inhibition. Biochem. J. 317, 385-388 (1996).
31. Drexler, H. C. Activation of the cell death program by inhibition of proteasome function. Proc. Natl Acad. Sci. USA 94, 855-860 (1997).
32. Grimm, L. M., Goldberg, A. L., Poirier, G. G., Schwartz, L. M. & Osborne, B. A. Proteasomes play an essential role in thymocyte apoptosis. EMBO J. 15, 3835-3844 (1996).
33. Sadoul, R. et al. Involvement of the proteasome in the programmed cell death of NGF-deprived sympathetic neurons. EMBO J. 15, 3845-3852 (1996).
34. Grimm, L. M. & Osborne, B. A. Apoptosis and the proteasome. Results Probl. Cell Differ. 23, 209-228 (1999).
35. Miyashita, T., Harigai, M., Hanada, M. & Reed, J. C. Identification of a p53-dependent negative response element in the Bcl-2 gene. Cancer Res. 54, 3131-3135 (1994).
36. Sadot, E., Geiger, B., Oren, M. & Ben-Ze'ev, A. Down-regulation of β-Catenin by activated p53. Mal. Cell. Biol. 21, 6768-6781 (2001).
37. Amson, R. B. et al. Isolation of 10 differentially expressed cDNAs in p53-induced apoptosis: activation of the vertebrate homologue of the Drosophila seven in absentia gene. Proc. Natl Acad. Sci. USA 93, 3953-3957 (1996).
38. Wu, G. S. et al. KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nature Genet. 17, 141-143 (1997).
39. Muller, M. et al. p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs. J. Exp. Med. 188, 2033-2045 (1998).
40. Stambolic, V. et al. Regulation of PTEN transcription by p53. Mol. Cell 8, 317-325 (2001).
41. Fortin, A. et al. APAF1 is a key transcriptional target for p53 in the regulation of neuronal cell death. J. Cell Biol. 155, 207-216 (2001).
42. Ryan, K. M., Phillips, A. C. & Vousden, K. H. Regulation and function of the p53 tumor suppressor protein. Curr. Opin. Cell Biol. 13, 332-337 (2001). References 35-42 report on key regulators of apoptosis as transcriptional targets of p53.
43. Marchenko, N. D., Zaika, A. & Moll, U. M. Death signal-induced localization of p53 protein to mitochondria. A potential role in apoptotic signaling. J. Biol. Chem. 275, 16202-16212 (2000).
44. Bennett, M. et al. Cell surface trafficking of Fas: a rapid mechanism of p53-mediated apoptosis. Science 282, 290-293 (1998).
45. Fang, S., Jensen, J. P., Ludwig, R. L., Vousden, K. H. & Weissman, A. M. Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53. J. Biol. Chem. 275, 8945-8951 (2000).
46. Haupt, Y., Maya, R., Kazaz, A. & Oren, M. Mdm2 promotes the rapid degradation of p53. Nature 387, 296-299 (1997).
47. Kubbutat, M. H., Jones, S. N. & Vousden, K. H. Regulation of p53 stability by Mdm2. Nature 387, 299-303 (1997). References 46 and 47 identify Mdm2-promoted degradation of p53 as a mechanism to ensure effective termination of the p53 signal.
48. Boyd, S. D., Tsai, K. Y. & Jacks, T. An intact HDM2 RING-finger domain is required for nuclear exclusion of p53. Nature Cell Biol. 2, 563-568 (2000).
49. Geyer, R. K., Yu, Z. K. & Maki, C. G. The MDM2 RING-finger domain is required to promote p53 nuclear export. Nature Cell Biol. 2, 569-573 (2000).
50. Hsieh, J. K. et al. RB regulates the stability and the apoptotic function of p53 via MDM2. Mol. Cell 3, 181-193 (1999).
51. Sharp, D. A., Kratowicz, S. A., Sank, M. J. & George, D. L. Stabilization of the MDM2 oncoprotein by interaction with the structurally related MDMX protein. J. Biol. Chem. 274, 38189-38196 (1999).
52. Zhang, Y. & Xiong, Y. Mutations in human ARF exon 2 disrupt its nucleolar localization and impair its ability to block nuclear export of MDM2 and p53. Mol. Cell 3, 579-591 (1999).
53. Fuchs, S. Y. et al. JNK targets p53 ubiquitination and degradation in nonstressed cells. Genes Dev. 12, 2658-2663 (1998).
54. Pagano, M. et al. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 269, 682-685 (1995).
55. Vlach, J., Hennecke, S. & Amati, B. Phosphorylation-dependent degradation of the cyclin-dependent kinase inhibitor p27. EMBO J. 16, 5334-5344 (1997).
56. Nakayama, K. et al. Targeted disruption of Skp2 results in accumulation of cyclin E and p27(Kip1), polyploidy and centrosome overduplication. EMBO J. 19, 2069-2081 (2000).
57. Roy, N., Deveraux, Q. L., Takahashi, R., Salvesen, G. S. & Reed, J. C. The c-IAP-1 and c-IAP-2 proteins are direct inhibitors of specific caspases. EMBO J. 16, 6914-6925 (1997).
58. Deveraux, Q. L., Takahashi, R., Salvesen, G. S. & Reed. J. C. X-linked IAP is a direct inhibitor of cell-death proteases. Nature 388, 300-304 (1997). This study uncovers the function of IAPs as caspase inhibitors.
59. Deveraux, Q. L. et al. IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases. EMBO J. 17, 2215-2223 (1998).
60. Hauser, H. P., Bardroff, M., Pyrowolakis, G. & Jentsch, S. A giant ubiquitin-conjugating enzyme related to IAP apoptosis inhibitors. J. Cell Biol. 141, 1415-1422 (1998). The identification of a ubiquitin-conjugating enzyme with a BIR domain.
61. Joazeiro, C. A. & Weissman, A. M. RING finger proteins: mediators of ubiquitin ligase activity. Cell 102, 549-552 (2000).
62. Yang, Y., Fang, S., Jensen, J. P., Weissman, A. M. & Ashwell, J. D. Ubiquitin protein ligase activity of IAPs and their degradation in proteasomes in response to apoptotic stimuli. Science 288, 874-877 (2000). Report on the autoubiquitylation and degradation of IAPs as a key event in the apoptotic programme.
63. Huang, H. et al. The inhibitor of apoptosis, cIAP2, functions as a ubiquitin-protein ligase and promotes in vitro monoubiquitination of caspases 3 and 7. J. Biol. Chem. 275, 26661-26664 (2000).
64. Suzuki, Y., Nakabayashi, Y. & Takahashi, R. Ubiquitin-protein ligase activity of X-linked inhibitor of apoptosis protein promotes proteasomal degradation of caspase-3 and enhances its anti-apoptotic effect in Fas-induced cell death. Proc. Natl Acad. Sci. USA 98, 8662-8667 (2001). The first study to provide evidence that an IAP can promote the degradation of an active caspase in living cells.
65. Karin, M. & Ben-Neriah, Y. Phosphorylation meets ubiquitination: the control of NF-κB activity. Annu. Rev. Immunol. 18, 621-663 (2000).
66. Palombella, V. J., Rando, O. J., Goldberg, A. L. & Maniatis, T. The ubiquitin-proteasome pathway is required for processing the NF-κB1 precursor protein and the activation of NF-κB. Cell 78, 773-785 (1994). This report provides evidence that the ubiquitln/proteasome pathway functions in the regulated processing of NF-κB precursors into active proteins.
67. Coux, O. & Goldberg, A. L. Enzymes catalyzing ubiquitination and proteolytic processing of the p105 precursor of nuclear factor κB1. Biol. Chem. 273, 8820-8828 (1998).
68. Hayashi, T. & Faustman, D. Essential role of human leukocyte antigen-encoded proteasome subunits in NF-κB activation and prevention of tumor necrosis factor-α induced apoptosis. J. Biol. Chem. 275, 5238-5247 (2000).
69. Deng, L. et al. Activation of the IκB kinase complex by TRAF6 requires a dimeric ubiquitin-conjugating enzyme complex and a unique poiyubiquitin chain. Cell 103, 351-361 (2000). By showing that IKK is activated through the assembly of Lys63-linked multiubiquitin chains, this study unveils a new regulatory function for ubiquitin in the activation of the NF-κKB pathway.
70. Wang, C. et al. TAK1 is a ubiquitin-dependent kinase of MKK and IKK. Nature 412, 346-351 (2001). This study extends the finding that kinases can be activated by ubiquitylation.
71. Tanaka, M. et al. Embryonic lethality, liver degeneration, and impaired NF-κB activation in IKK-β-deficient mice. Immunity 10, 421-429 (1999).
72. Wang, C. Y., Mayo, M. W., Korneluk, R. G., Goeddel, D. V. & Baldwin, A. S. Jr. NF-κB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 281, 1680-1683 (1998).
73. Wu, M. X., Ao, Z., Prasad, K. V., Wu, R. & Schlossman, S. F. IEX-1L, an apoptosis inhibitor involved in NF-κB-mediated cell survival. Science 281, 998-1001 (1998).
74. Zong, W. X., Edelstein, L. C., Chen, C., Bash, J. & Gelinas, C. The prosurvival Bcl-2 homolog Bfl-1/A1 is a direct transcriptional target of NF-κB that blocks TNFα-induced apoptosis. Genes Dev. 13, 382-387 (1999).
75. Kreuz, S., Siegmund, D., Scheurich, P. & Wajant, H. NF-κB inducers upregulate cFLIP, a cyctoheximide-sensitive inhibitor of death receptor signaling. Mol. Cell. Biol. 21, 3964-3973 (2001).
76. Grossmann, M. et al. The anti-apoptotic activities of Rel and RelA required during B-cell maturation involve the regulation of Bcl-2 expression. EMBO J. 19, 6351-6360 (2000). References 63-67 identify key regulators of apoptosis as gene targets of NF-κB transcriptional activity.
77. Tang, G. et al. Inhibition of JNK activation through NF-κB target genes. Nature 414, 313-317 (2001).
78. De Smaele, E. et al. Induction of Gadd45β by NF-κB downregulates pro-apoptotic JNK signalling. Nature 414, 308-313 (2001).
79. Barkett, M. & Gilmore, T. D. Control of apoptosis by Rel/NF-κB transcription factors. Oncogene 18, 6910-6924 (1999).
80. Connolly, J. L. et al. Reovirus-induced apoptosis requires activation of transcription factor NF-κB. J. Virol. 74, 2981-2989 (2000).
81. Kasibhatla, S. et al. DNA damaging agents induce expression of Fas ligand and subsequent apoptosis in T lymphocytes Via the activation of NF-κB and AP-1. Mol. Cell 1, 543-551 (1998).
82. Rivera-Walsh, I., Waterfield, M., Xiao, G., Fong, A. & Sun, S. C. NF-κB signaling pathway governs TRAIL gene expression and human T-cell leukemia virus-I tax-induced T-cell death. J. Biol. Chem. 276, 40385-40388 (2001).
83. Dimmeler, S., Breitschopf, K., Haendeler, J. & Zeiher, A. M. Dephosphorylation targets Bcl-2 for ubiquitin-dependent degradation: a link between the apoptosome and the proteasome pathway. J. Exp. Med. 189, 1815-1822 (1999).
84. Breitschopf, K., Haendeler, J., Malchow, P., Zeiher, A. M. & Dimmeler, S. Posttranslational modification of Bcl-2 facilitates its proteasome-dependent degradation: molecular characterization of the involved signaling pathway. Mol. Cell. Biol. 20, 1886-1896 (2000).
85. Marshansky, V. et al. Proteasomes modulate balance among proapoptotic and antiapoptotic Bcl-2 family members and compromise functioning of the electron transport chain in leukemic cells. J. Immunol. 166, 3130-3142 (2001).
86. Breitschopf, K., Zeiher, A. M. & Dimmeler, S. Ubiquitin-mediated degradation of the proapoptotic active form of bid. A functional consequence on apoptosis induction. J. Biol. Chem. 275, 21648-21652 (2000).
87. Thomas, M. & Banks, L. Inhibition of Bak-induced apoptosis by HPV-18 E6. Oncogene 17, 2943-2954 (1998).
88. Li, B. & Dou, Q. P. Bax degradation by the ubiquitin/proteasome-dependent pathway: involvement in tumor survival and progression. Proc. Natl Acad. Sci. USA 97, 3850-3855 (2000).
89. Peter, M. E., Heufelder, A. E. & Hengartner, M. O. Advances in apoptosis research. Proc. Natl Acad. Sci. USA 94, 12736-12737 (1997).
90. Kitada, T. et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392, 605-608 (1998).
91. Shimura, H. et al. Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nature Genet. 25, 302-305 (2000).
92. Cummings, C. J. et al. Mutation of the E6-AP ubiquitin ligase reduces nuclear inclusion frequency while accelerating polyglutamine-induced pathology in SCA1 mice. Neuron 24, 879-892 (1999).
93. Saigoh, K. et al. Intragenic deletion in the gene encoding ubiquitin carboxy-terminal hydrolase in gad mice. Nature Genet. 23, 47-51 (1999).
94. Yuan, J. & Yankner, B. A. Apoptosis in the nervous system, Nature 407, 802-809 (2000).
95. Huang, P. & Oliff, A. Signaling pathways in apoptosis as potential targets for cancer therapy. Trends Cell Biol. 11, 343-348 (2001).
96. Baldwin, A. S. Jr. Series introduction: the transcription factor NF-κB and human disease. J. Clin. Invest. 107, 3-6 (2001).
97. Bondeson, J., Foxwell, B., Brennan, F. & Feldmann, M. Defining therapeutic targets by using adenovirus: blocking NF-κB inhibits both inflammatory and destructive mechanisms in rheumatoid synovium but spares anti-inflammatory mediators. Proc. Natl Acad. Sci. USA 96, 5668-5673 (1999).
98. Wang, C. Y., Cusack, J. C. Jr, Liu, R. & Baldwin, A. S. Jr. Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-κB. Nature Med. 5, 412-417 (1999).
99. Perkins, N. D. The Rel/NF-κB family: friend and foe. Trends Biochem Sci. 25, 434-440 (2000).
100. Lee, D. H. & Goldberg, A. L. Proteasome inhibitors: valuable new tools for cell biologists. Trends Cell Biol. 8, 397-403 (1998).
101. Adams, J. et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res. 59, 2615-2622 (1999).
102. Mlynarczuk, I. et al. Augmented pro-apoptotic effects of TRAIL and proteasome inhibitor in human promonocytic leukemic U937 cells. Anticancer Res. 21, 1237-1240 (2001).
103. Milligan, S. A. & Nopajaroonsri, C. Inhibition of NF-κB with proteasome inhibitors enhances apoptosis in human lung adenocarcinoma cells in vitro. Anticancer Res. 21, 39-44 (2001).
104. Mitsiades, C. S. et al. TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications. Blood 98, 795-804 (2001).
105. Franco, A. V. et al. The role of NF-κB in TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis of melanoma cells. J. Immunol. 166, 5337-5345 (2001).
106. Shah, S. A. et al. 26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer. J. Cell Biochem. 82, 110-122 (2001).
107. Cusack, J. C. Jr et al. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-κB inhibition. Cancer Res. 61, 3535-3540 (2001).
108. Teicher, B. A., Ara, G., Herbst, R., Palombella, V. J. & Adams, J. The proteasome inhibitor PS-341 in cancer therapy. Clin. Cancer Res. 5, 2638-2645 (1999).
109. Cheng, E. H. et al. BCL-2, BCL-X(L) sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis. Mol. Cell 8, 705-711 (2001).
110. Koegl, M. et al. A novel ubiquitination factor, E4, is involved in multiubiquitin chain assembly. Cell 96, 635-644 (1999).